Your Dose of Cannabis Education
Your Dose of Cannabis Education
Only have a minute but want to Learn something every day™? Sign up to receive Your Dose of Cannabis Education, bringing featured content from our course library right to your inbox each day.
Your Dose of Cannabis Education is based on data from the studies and reviews published in the current peer-reviewed medical journals. Whether you are a healthcare provider, patient, caregiver, an individual working in the healthcare sector, or just a curious person, you can benefit from Your Dose of Cannabis Education.
Wake up every morning and get your dose of unbiased evidence-based cannabis education!
2025-06-27
Some patients use cannabinoid-based medicines to treat nausea and vomiting. Is one of the side effects of cannabinoid-based medicines nausea and vomiting?
Yes.. The adverse event profile of cannabinoid-based formulations is dependent upon the ratio of CBD:THC, the presence of other cannabinoids and terpenes, and the dose consumed. The known common adverse effects of cannabinoid-based medicines include sedation/somnolence, dizziness, anxiety, cognitive dysfunction, nausea, vomiting, diarrhea, vertigo, increased or decreased appetite and dry mouth. Brenneisen R, Egli A, ElSohly MA, Henn V, Spiess Y. The effect of orally and rectally administered delta9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int. J. Clin. Pharmacol. Ther. 1996 Oct;34(10)446-52. https://pubmed.ncbi.nlm.nih.gov/8897084/
2025-06-26
How should a clinician monitor the outcome of cannabinoid-based therapy?
As suggested by the Australian Centre for Cannabinoid Clinical and Research Excellence, monitoring should initially involve reviewing the patient weekly in person, and via phone if required in the interim between clinical reviews.
"There are three areas of outcomes that should be considered: 1. Symptom control - "A pre-defined measure of success should be negotiated with the patient prior to commencement of therapy. This can be measured by using a validated tool, for example by the Palliative Care Symptom Assessment Scale. " 2. Drug adverse events - "Careful monitoring of patients for adverse events and the need for a change in dosage is important. Adverse events may become apparent after commencement or after change in dose...Adverse events may be related to other concurrent medications. Doses of these medicines should be adjusted as appropriate. " 3. Pathology monitoring - "Drug concentrations of drugs where there is a potential or actual drug-drug interaction may be important. Cannabidiol may cause hepatocellular injury. Patient’s liver function biochemistry should be monitored prior to initiation and periodically as clinically indicated."Prescribing Cannabis Medicines for Chronic Non-cancer Pain v2 September 2019 c10. - by the Australian Centre for Cannabinoid Clinical and research Excellence https://www.ces.edu.co/wp-content/uploads/2020/09/acre-prescribing-guidance-chronic-non-cancer-pain.pdf
2025-06-25
How long should the testing period of a cannabinoid-based drug be?
According to the European Pain Federation position paper on the appropriate use of cannabis-based medicines, a testing period of maximum 3 months should be considered both by patients and prescribers [or recommenders], to assess treatment efficacy and safety. At the end of this testing period, long_term treatment should only be considered with significant improvement and lack of safety issues.If a satisfactory outcome is achieved, the patient should remain under close medical surveillance for the duration of cannabis_based medicine therapy If the predefined treatment goals are not achieved and/or unacceptable burden of side effects occur and/or signs of abuse and misuse are observed, the specific cannabis_based medicines should be safely withdrawn and alternative options actively explored.Huser, W, Finn, DP, Kalso, E, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis_based medicines and medical cannabis for chronic pain management. Eur J Pain.. 2018; 22: 1547Đ 1564. https://pubmed.ncbi.nlm.nih.gov/30074291/
2025-06-24
Considering the pharmacokinetics of orally consumed cannabinoid-based food products, how should the oral consumption of cannabinoids proceed?
According to Health Canada's document entitled Information for Health Care Professionals: Cannabis and Cannabinoids, consumption of oral cannabis should proceed slowly, waiting a minimum of 30 minutes, but preferably 3 h, between bites of cannabis-based oral products (e.g. cookies, baked goods) to gauge for strength of effects or for possible overdosing.Information for Health Care Professionals Đ Cannabis (marihuana, marijuana) and the Cannabinoids Đ Dried or fresh plant and oil for administration by ingestion or other means Psychoactive agent. This document can be found at https://www.canada.ca/content/dam/hc-sc/documents/services/drugs-medication/cannabis/information-medical-practitioners/information-health-care-professionals-cannabis-cannabinoids-eng.pdf
2025-06-23
Does pretreatment with CBD prevent the transient psychotic symptoms induced by THC?
According to a study in humans, pretreatment with CBD does diminish THC's psychotic effects. This particular study involved 6 healthy volunteers who were given THC intravenously on two separate occasions Đ once with a placebo pretreatment and once with a CBD pretreatment.Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol 2012 Dec; 2(6):241-254. doi:10.1177/2045125312457586. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736954/
feed…New to TheAnswerPage? There’s lots we’d like to share with you and we don’t want you to miss a thing! Be sure to register today for “Your Dose of Cannabis Education” emails where you’ll gain valuable insights in small doses that fit your schedule and also be provided direct access to the archived daily content.